1. Home
  2. ENTA vs ABEO Comparison

ENTA vs ABEO Comparison

Compare ENTA & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

N/A

Current Price

$13.23

Market Cap

378.0M

Sector

Health Care

ML Signal

N/A

Logo Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc.

N/A

Current Price

$5.84

Market Cap

399.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTA
ABEO
Founded
1995
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
378.0M
399.5M
IPO Year
2012
2005

Fundamental Metrics

Financial Performance
Metric
ENTA
ABEO
Price
$13.23
$5.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$20.40
$20.00
AVG Volume (30 Days)
204.2K
1.5M
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
165.16
EPS
N/A
N/A
Revenue
$102,814,000.00
$2,998,000.00
Revenue This Year
$7.76
$1,024.31
Revenue Next Year
N/A
$145.42
P/E Ratio
N/A
N/A
Revenue Growth
16.48
258.18
52 Week Low
$7.05
$4.00
52 Week High
$17.15
$7.65

Technical Indicators

Market Signals
Indicator
ENTA
ABEO
Relative Strength Index (RSI) 45.89 40.77
Support Level $12.48 $5.71
Resistance Level $13.98 $5.85
Average True Range (ATR) 0.62 0.18
MACD -0.03 -0.02
Stochastic Oscillator 18.47 22.60

Price Performance

Historical Comparison
ENTA
ABEO

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Share on Social Networks: